268 related articles for article (PubMed ID: 19755677)
21. Azacitidine.
Issa JP; Kantarjian HM; Kirkpatrick P
Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
[No Abstract] [Full Text] [Related]
22. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in
Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
Leuk Lymphoma; 2019 Dec; 60(13):3316-3319. PubMed ID: 31204875
[No Abstract] [Full Text] [Related]
23. Optimizing hypomethylating agents in myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
[TBL] [Abstract][Full Text] [Related]
24. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
25. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
[TBL] [Abstract][Full Text] [Related]
27. 5-Azacytidine/Azacitidine.
Müller A; Florek M
Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
[TBL] [Abstract][Full Text] [Related]
28. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
29. [Demethylating medication in myelodysplastic syndrome].
Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
[TBL] [Abstract][Full Text] [Related]
30. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
Wijermans P; Lübert M
Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
[TBL] [Abstract][Full Text] [Related]
32. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
Steensma DP; Stone RM
Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplasia, megakaryocytes, and methylation.
Steensma DP
Leuk Res; 2004 Aug; 28(8):775-6. PubMed ID: 15203274
[No Abstract] [Full Text] [Related]
34. Review: recent clinical trials in epigenetic therapy.
Oki Y; Issa JP
Rev Recent Clin Trials; 2006 May; 1(2):169-82. PubMed ID: 18473969
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
Takahashi Y; Kimura S; Okano M
Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
[No Abstract] [Full Text] [Related]
36. Drug therapy for myelodysplastic syndrome: building evidence for action.
Tefferi A; Letendre L
Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
[No Abstract] [Full Text] [Related]
37. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.
Grövdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellström-Lindberg E
Leukemia; 2014 Feb; 28(2):411-3. PubMed ID: 24025691
[No Abstract] [Full Text] [Related]
38. Silencing the critics: new studies move closer to answering epigenetic questions.
Tuma RS
J Natl Cancer Inst; 2004 Nov; 96(22):1652-3. PubMed ID: 15547174
[No Abstract] [Full Text] [Related]
39. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R; Zwergel C; Mai A; Valente S
Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
[TBL] [Abstract][Full Text] [Related]
40. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
